Gates’ $2.5 Billion Women’s Health Bet: Will Private Capital Be Ready to Catch It?
History shows that catalytic grants spark breakthroughs but lasting impact depends on private capital stepping in at the right moment.
This newsletter is free. But it takes hours each week to research, write, and produce at this level. Here are 5 ways to support my work: 1. click “❤️” to amplify 2. subscribe 3. share this publication 4. buy me coffee 5. become a partner
Connect and collaborate with me here! Email | LinkedIn | Instagram
In the late 1970s and early 1980s, Ian Frazer wasn’t thinking about women’s health or billion-dollar drug markets.
He was an immunologist studying how papillomaviruses tricked the immune system in animals as well as in HIV patients with stubborn genital warts. It was niche work: slow, publicly funded, and far from any investor’s radar.
When he met Chinese virologist Jian Zhou at Cambridge, the two began experimenting with the idea of building a hollow “shell” of the human papillomavirus; a virus-like particle that could trigger immunity without infection. By 1991, they had filed a provisional patent.
That work became the foundation for Gardasil and Cervarix which are vaccines now protecting millions of women from cervical cancer and generating billions in revenue for the companies that scaled them.
They remain among the most important women’s health innovations in modern medicine.
New Here?
If you are an investor, operator, or women’s health advocate, start here.
→ Preorder the book: The Billion Dollar Blind Spot
→ Subscribe to the podcast: Blindspot Capital launched this month!
→ Join the Women’s Health Investing Masterclass & Choose your Tier: Core Access, Premium Access or Lite Access
A USD $2.5 Billion Bet on Women’s Health
This month, the Gates Foundation made a USD 2.5 billion bet that history could repeat itself.
Through 2030, they will fund more than forty women’s health innovations across maternal care, menstrual and gynecological health, contraceptive innovation, STIs, and maternal nutrition.
Research into the vaginal microbiome.
First-in-class therapeutics for preeclampsia.
Non-hormonal contraception.
Bill Gates put it plainly: “Women’s health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change.”
Every one of these project will start where HPV was in the 1980s: critical science, not yet an investable product. And like HPV, their survival will depend on what happens when the grant money runs off.
Science Isn’t the Same as Investability
Here’s the part we are not saying out loud: Breakthrough science isn’t the same as a bankable deal.
In today’s markets, taking science from the research lab to the clinic usually depends on venture and growth equity capital. These are the vehicles we use to commercialize innovation.
But these vehicles are built for speed: seven-year fund cycles, high IRR pressure, clean biomarkers, and quick adoption curves.
But women’s health rarely works like that. Because biology moves slower. Regulatory endpoints are messier, and markets need educating before they adopt and scale.
I have seen what happens when the science is ready but the market isn’t.
A diagnostics company with airtight data, shelved for years because no one wanted to fund the slog of reimbursement approval. The clinical evidence was strong, the patient need obvious but investors couldn’t see through the haze of slow payor timelines.
A contraceptive innovation licensed for pennies to an incumbent who buried it in a portfolio, waiting for the “right time” to commercialize.
These are not cautionary tales. These are the realities of a system that still hasn’t designed itself to catch women’s health innovations at the handover point from public or philanthropic funding.
❤️ Enjoying this? If this post sparked something for you, click the ❤️ at the bottom. It helps more than you know and tells me you're reading.
Designing Capital to Catch the Handover
If the Gates funding is the foundation, we need architects ready to build once that foundation is in place. Private capital that can take the baton and run the second leg, translating breakthrough science into scalable products, viable companies, and market-shaping categories.
So what if we had dedicated women’s health growth vehicles with 8–12 year timelines? Timelines long enough to match the tempo of biology, regulatory approval, and adoption curves. Vehicles designed not for the sprint of a seven-year fund, but for the marathon of healthcare innovation.
This is not a utopian idea. It’s a structure that already exists in other sectors; in climate tech, in rare diseases, in oncology where long horizons and complex science are seen as worth the wait.
And the same toolkit could go further: corporate venture arms investing earlier when valuations are sane; blended finance models where foundations take the first loss so commercial LPs can take the scale-up win; strategic consortia pooling trial infrastructure and distribution.
Each of these models already works elsewhere. Women’s health deserves the same level of design, discipline, and conviction.
Because when the science is ready, the question won’t be whether it can change lives. It will be whether the capital is ready to let it.
Will We Be Ready This Time?
Every USD $1 invested in women’s health returns an estimated USD $3 in economic growth. Closing the gender health gap could add USD $1 trillion to the global economy by 2040.
The HPV vaccine was never meant to be a women’s health story until it was. And like the HPV vaccine, some of these Gates-backed projects will make the same journey: from obscure science to indispensable innovation.
The only question is:
Will we be ready this time?
Or a decade from now, will the molecules have changed but the blind spot remained?
If this essay moved you, share or restack it.
Public pressure and narrative power change incentives but only when we show up.
Those who can fund the future, should. But every one of us can amplify the future we want to see. Share this with your network. Because the future of care depends on who speaks up and who gets heard.
Pre-order my upcoming book The Billion Dollar Blind Spot to learn why women’s health is the future of healthcare investing.
Join Our Network
Are you building or backing credible, under-the-radar solutions in women’s health?
We want to hear from you. Reach out privately or reply to this post. FHV curates brands and breakthroughs that deserve broader attention in the women’s health ecosystem.
I write weekly at FemmeHealth Ventures Alliance about capital, care, and the future of overlooked markets. If you are building, backing, or allocating in this space, I’d love to connect.
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.
Bill Gates has a gross infatuation with Africa's population and African women's bodies. He wanted to use the Continent for testing covid-19 vaccines, and walked it back after swift and rightly harsh criticism.
Now he's offering "family planning" services with an 8 year contraceptive. Whites are declining as Musk and other billionaires have been going on about, and are wanting to interfere with the growth of the Global Majority.
As Business Insider Africa highlights(link below) Africa's advantage over western hegemony is its population growth.
The need for these services is desperate both there and here in the US, and they know it.
In addition, this comes at a time when white christian nationalists have been sending "missionaries" seeding anti-democratic and anti-LGBTQ+ rhetoric. And this is being launched under the Trump regime, so no oversight.
https://africa.businessinsider.com/local/lifestyle/gates-foundations-new-world-first-contraceptive-for-african-women-what-it-means-for/gx9bryj
https://thegrio.com/2023/07/06/white-christian-nationalists-are-exporting-homophobia-and-pushing-antigay-laws-in-africa/
This is important. Sharing.